Firmonertinib
FURMO-006
Phase 3 small_molecule active
Quick answer
Firmonertinib for Non-Small-Cell Lung Cancer is a Phase 3 program (small_molecule) at ArriVent BioPharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ArriVent BioPharma
- Indication
- Non-Small-Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active